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Abstract
The P2Y12 receptor plays a crucial role in the regulation of platelet activation by several agonists, which is irreversibly
antagonized by the active metabolite of clopidogrel, a widely used anti-thrombotic drug. In this study, we investigated
whether reduction of platelet reactivity leads to reduced inflammatory responses using a rat model of erosive arthritis. We
evaluated the effect of clopidogrel on inflammation in Lewis rats in a peptidoglycan polysaccharide (PG-PS)-induced
arthritis model with four groups of rats: 1) untreated, 2) clopidogrel-treated, 3) PG-PS-induced, and 4) PG-PS-induced and
clopidogrel-treated. There were significant differences between the PG-PS+clopidogrel group when compared to the PG-PS
group including: increased joint diameter and clinical manifestations of inflammation, elevated plasma levels of pro-
inflammatory cytokines (IL-1 beta, interferon (IFN) gamma, and IL-6), an elevated neutrophil blood count and an increased
circulating platelet count. Plasma levels of IL-10 were significantly lower in the PG-PS+clopidogrel group compared to the
PG-PS group. Plasma levels of platelet factor 4 (PF4) were elevated in both the PG-PS and the PG-PS+clopidogrel groups,
however PF4 levels showed no difference upon clopidogrel treatment, suggesting that the pro- inflammatory effect of
clopidogrel may be due to its action on cells other than platelets. Histology indicated an increase in leukocyte infiltration at
the inflammatory area of the joint, increased pannus formation, blood vessel proliferation, subsynovial fibrosis and cartilage
erosion upon treatment with clopidogrel in PG-PS-induced arthritis animals. In summary, animals treated with clopidogrel
showed a pro-inflammatory effect in the PG-PS-induced arthritis animal model, which might not be mediated by platelets.
Elucidation of the mechanism of clopidogrel-induced cell responses is important to understand the role of the P2Y12
receptor in inflammation.
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Introduction
The P2Y12 receptor is essential for ADP-induced platelet
aggregation [1,2,3] and in thrombus growth and stability [4]. Due
to its important role not only in ADP-induced but also in other
agonist-induced platelet functional responses, the P2Y12 receptor
has become a successful target for anti-thrombotic drugs. The
thienopyridine compounds such as clopidogrel and prasugrel are
first converted to an active metabolite in the liver and the active
metabolite irreversibly inactivates the P2Y12 receptor [5]. Ex vivo
inhibition of the P2Y12 receptor by clopidogrel administration
diminishes the rapid exposure of Tissue Factor, suggesting a role for
the P2Y12 receptor in the pro-coagulant activity of platelets [6].
Antagonism of the P2Y12 receptor diminishes the extent of
release from platelets of both the alpha and dense granules. The
dense granules contain ADP and ATP which act on platelets and
other bloods cells upon release [7]. Extracellular ATP has been
shown to trigger mobilization of intracellular calcium stores in
freshly isolated human neutrophils and monocytes, which results
in either direct stimulation of some inflammatory responses or
enhanced responsiveness to agonists [8]. The alpha granules
contain several growth factors as well as chemokines that stimulate
peripheral blood leukocytes [9,10,11,12]. In addition, the P2Y12
receptor has been shown to potentiate arachidonic acid liberation,
which can be converted to thromboxane A2 in platelets and to
leukotrienes in peripheral blood leukocytes [13]. The leukotrienes
thus generated play an important role in the inflammatory
responses. Hence, platelet activation leading to release of granule
contents and arachidonic acid liberation has been thought to
contribute to inflammatory responses.
Rheumatoid arthritis (RA) is one of the most prevalent
inflammatory diseases afflicting humans and several animal models
are available that mimic the erosive arthritis in this pathological
condition [14]. One such animal model applicable to the study of
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8joint inflammation is the induction of erosive arthritis by peptidogly-
can-polysaccharide (PG-PS) in susceptible animals [14,15,16]. PG-PS
is a purified form of a polymer extracted from Group A Streptococcus
cell walls [14]. When PG-PS is injected intraperitoneally (i.p.) in
arthritis-susceptible species such as Lewis rat, it induces a chronic,
erosive, and recurrent poly-arthritis, known to resemble human
rheumatoid arthritis in clinical, histological and radiological detail
[16,17]. The primary immunogenic moiety of the PG-PS is the
peptidoglycan. Arthritis develops as early as two days after PG-PS
administration for a period of three to five days (acute phase),
mediated by the complement system [18]. The arthritis-induced
animal shows a remission period between 4 to 10 days followed by
spontaneousreactivationofthejointinflammationthatlastforseveral
weeks (chronic phase). This phase might be mediated by T cells
proliferation and infiltration. In human RA there is evidence for
platelet activation [19], which in turn may lead to neutrophil
stimulation [20,21,22]. The PG-PS model thus represents an ideal
experimental animal model to test potential drug interventions
targeting platelets.
Antagonizing the P2Y12 receptors on platelets reduces the
release of the granule contents [23]. Several anti-thrombotic drugs,
such as clopidogrel, can act on the P2Y12 receptor thereby
reducing platelet activation and granule release [24,25]. Activated
platelets release pro-inflammatory cytokines and nucleotides from
granules at the site of vascular injury and as a result may trigger
inflammation and thrombosis [26]. In addition, activated platelets
release a number of chemokines from alpha granules that activate
leukocytes [11]. Boilard et al. [19] identified micro-particles
generated by activated platelets in joint fluid from RA patients.
Although clopidogrel is a potent anti-thrombotic agent acting
through the P2Y12 receptor, the effects of P2Y12 receptor
antagonists have not been fully evaluated on chronic inflammatory
responses. Therefore, in this study, we used clopidogrel in the PG-
PS-induced arthritis model to evaluate its effects on inflammation.
Results
Clopidogrel increases the clinical and pathological
manifestations of PG-PS-induced arthritis
Untreated animals and those treated with clopidogrel alone
showed no changes in joint diameters during the course of the
study. The effect of clopidogrel in this last group was tested during
the course of the experimental protocol to assess a non-response
pattern of platelets in response to ADP (data not shown). PG-PS-
induced arthritic animals treated and untreated with clopidogrel
showed an increase in the ankle joint diameter during both the
acute and chronic phases. The increased joint diameter in PG-PS-
induced arthritic animals was exacerbated in the group combining
PG-PS with clopidogrel when compared with PG-PS alone and
this joint diameter increase was significant during days 15 to 21
(***p,0.0001) (Figure 1).
Histopathological changes were also seen between the groups.
Untreated animals and those dosed with clopidogrel alone did not
show any inflammatory changes. However, in PG-PS-treated
animals there was a diffuse infiltration of inflammatory cells with
severe synovial thickening, pannus formation, blood vessel
proliferation, subsynovial fibrosis, subchondral inflammation and
cartilage erosion. PG-PS-treated animals alone or in combination
with clopidogrel exhibited a greater change in the joint
inflammatory process. These changes observed were more
pronounced in the PG-PS in combination with clopidogrel when
compared with PG-PS alone (Figure 2). Inflammatory changes
were measured and pathological scores were assigned as explained
in detail in Materials and Methods. Scores for synoviocyte
hyperplasia (in both acute and chronic phases), blood vessel
proliferation (chronic), inflammatory infiltration (acute and
chronic) and fibrosis (chronic) were increased in the PG-PS-
treated animals in combination with clopidogrel when compared
to the PG-PS-treated animals alone, *p,0.05 (Figure 3, panels A–
D). Hind paw histopathological scoring system was used to assess
the inflammatory responses, as reported previously [27]. A score of
zero indicates a lack of inflammation, which was observed in both
untreated animals and those dosed with clopidogrel alone. PG-PS-
treated animals had an average score of 5.7560.96 at day 5 rising
up to 10.1764.79 at day 21 (vs. untreated and clopidogrel-treated
groups, p,0.05). PG-PS-treated animals in combination with
clopidogrel demonstrated a significant increase in the histopath-
ological score average, up to 7.2560.5 at day 5 rising up to
16.5665.81 at day 21 (vs. PG-PS-treated group p,0.05 for both
day 5 and day 21, Figure 3, Panel E.) In summary, the data
indicate that PG-PS administered in combination with clopidogrel
is associated with marked inflammatory changes when compared
with PG-PS alone.
Figure 1. Effect of clopidogrel on the PG-PS-induced arthritis
animal model. (A) Measurements of ankle joint diameter. Values
represent the change of paw diameter in millimeters. Changes of paw
diameter observed in the PG-PS+clopidogrel group were significantly
increased when compare to the PG-PS group from day 15 to day 21,
***p,0.0001. (B) Photographic images of paw and ankle joints of the
animals on day 5 and day 21.
doi:10.1371/journal.pone.0026035.g001
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associated with thrombocytosis, neutrophilia and
leukocytosis
Upon completion of the two phases of the study, hematological
parameters were evaluated in each group. There were no
differences in the hematological parameters in clopidogrel-treated
animals compared to untreated animals. In contrast, significant
increases in total circulating leukocytes and neutrophils were
observed in PG-PS-treated animals as well as PG-PS-treated
animals in combination with clopidogrel, compared to untreated
animals (p,0.05, Figure 4). Interestingly, platelet numbers were
not significantly different in PG-PS-treated animals compared to
untreated animals, but they increased significantly in PG-PS plus
clopidogrel-treated animals in the chronic phase. Liver and kidney
function was evaluated in all groups and did not account for the
hematological changes described above (Table 1).
Clopidogrel administration in combination with PG-PS
alters the plasma cytokine profile
Inflammatory responses are regulated by both pro-inflammato-
ry and anti-inflammatory cytokines [28]. Thus, plasma levels of
pro-inflammatory and anti-inflammatory cytokines in plasma were
evaluated during the chronic phase of the study, namely IL-1b, IL-
4, IL-6, IL-10, and IFN-c. Baseline levels of these cytokines were
unchanged in the untreated group or in the group treated with
clopidogrel alone. However, significant changes were observed in
the plasma levels of pro-inflammatory cytokines IFN-c, IL-6, and
IL-1b, in the PG-PS-treated animals, when compared with
untreated animals or animals that were treated with clopidogrel
alone. Furthermore, the pro-inflammatory cytokine profile was
augmented in the PG-PS-treated animals in combination with
clopidogrel when compared to PG-PS-treated alone (Figure 5).
Notably, the anticipated increased in the anti-inflammatory
cytokine IL-10 in response to PG-PS was blunted down to
baseline values in the PG-PS-treated animals in combination with
clopidogrel. Clopidogrel treatment alone was not responsible for
such changes since the baseline values when compared with
untreated group were not statistically significant (Figure 5). The
levels of IL-4, an anti-angiogenic cytokine, were not changed in
any of the four groups tested. PF4 plasma levels were increased in
all PG-PS-induced arthritis animals when compared to untreated
and clopidogrel-treated animals. However, treatment with clopi-
dogrel in induced arthritis animals did not differ from the induced
arthritis control animals.
To evaluate whether the use of PG-PS changed the platelet
response to clopidogrel, platelet aggregation studies were per-
formed in washed platelets from the four groups of animals.
Platelets from the PG-PS-treated animals stimulated with
2MeSADP, a P2Y12 agonist, showed normal aggregation and
secretion responses, compared to untreated animals. Platelets from
the PG-PS-treated and clopidogrel-dosed animals showed dimin-
Figure 2. Histology of the ankle joint of the animals. 106and 406magnification of paraffin-embedded ankle sections stained with H&E, for
the acute phase (day 5) and the chronic phase (day 21). The 406magnification on day 5 shows leukocyte infiltration in the PG-PS-induced arthritis
animals. Slides from the chronic phase in the PG-PS-induced arthritis animals showed fibrosis, pannus formation and severe leukocyte infiltration with
more pronounced effects observed in the clopidogrel-treated animals.
doi:10.1371/journal.pone.0026035.g002
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clopidogrel alone (Figure 6). Hence, PG-PS does not alter platelet
reactivity to P2Y12 agonists nor affect clopidogrel activity on
platelets.
Discussion
We investigated the effect of clopidogrel on a rat model of
erosive arthritis. Treatment with clopidogrel in animals with PG-
PS-induced arthritis led to a significant increase in joint diameter
and inflammation compared to animals with PG-PS-induced
arthritis alone. There were no inflammation or joint diameter
changes in animals treated with clopidogrel, indicating that
clopidogrel alone does not have any effect in the joints of normal
animals. However, clopidogrel in the presence of inflammation
aggravated the course of the disease. Additionally, the clinical
manifestations observed in the PG-PS-induced arthritic animals
treated with clopidogrel also demonstrated leukocytosis and
thrombocytosis.
The active metabolite of clopidogrel is normally metabolized in
the liver [5]. Since PG-PS has been shown to produce parenchyma
changes in the liver with granuloma formation [29], we measured
liver enzymes such as alkaline phosphatase, lipase, AST, and ALT.
There were no statistically significant changes among the
experimental groups, suggesting that the liver function is not
impaired (Table 1). Platelet aggregation was similar in both
clopidogrel-dosed and clopidogrel-dosed/PG-PS-treated animals,
indicating that PG-PS does not affect the generation of the active
metabolite of clopidogrel (Figure 6). Thus, PG-PS has no apparent
effect on liver function or clopidogrel metabolism to its active
form.
The levels of the pro-inflammatory cytokines (IL-1, IFN-c and
IL-6) were much higher in the PG-PS-induced animals treated
with clopidogrel compared to clopidogrel-treated animals alone.
Figure 3. Four pathological parameters and the histopathological score from the histological sections of the acute and chronic
phases. Synoviocyte hyperplasia (A), proliferative blood vessels (B), inflammatory infiltrates (C) sub-synovial fibrosis (D) and the histopathological
score (E). Values plotted are the mean of the measurements 6 SEM, (n=3 per group) *p,0.05, PG-PS-treated with clopidogrel group vs. PG-PS group.
Representation of the animals from the untreated and clopidogrel-treated groups was excluded to simplify graphs since these animals showed no
inflammatory changes.
doi:10.1371/journal.pone.0026035.g003
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26035Figure 4. Blood cell counts of rats following clopidogrel treatment in PG-PS- induced arthritis model. Leukocyte (A), neutrophil (B), and
platelet (C) cell blood counts at day 5 and day 21. All cell blood counts are plotted at 10
3/mL. Values are mean 6 SEM, (n=6), untreated group (black
bar), clopidogrel group (white bar), PG-PS group (light gray bar) and PG-PS-treated with clopidogrel group (dark gray bar), * p,0.05.
doi:10.1371/journal.pone.0026035.g004
Table 1. Complete chemistry profile of experimental animals.
Untreated Clopidogrel PG-PS PG-PS+Clopidogrel
CHOLESTEROL (mg/dL) 83.567.54 70614.85 83.25613.67 87.67614.57
TRIGLYCERIDES (mg/dL) 69.565.97 47.25614.1 64.75619.96 60.67617.1
ALT (u/L) 86.75650.92 56610.17 5564.08 46.6764.16
AST (u/L) 189.75680.51 117.50653.57 94630.6 117.34636.96
ALK (mg/dL) 233.75654.87 202638.01 240.75626.6 261662.23
TOTAL BILLIRUBIN (mg/dL) 0.2560.06 0.1860.1 0.2560.1 0.1360.06
TOTAL PROTEIN (g/dL) 5.3860.45 4.761.07 5.9360.57 6.3360.57
ALBUMIN (g/dL) 3.0560.35 2.261.04 2.7560.37 2.7760.35
GLUCOSE (mg/dL) 193.25636.44 211.5636.97 195.25633.33 182611
BUN (mg/dL) 18.7564.57 20.565.97 1963.16 1761.73
CREATININE (mg/dL) 0.3360.22 0.4360.1 0.4360.05 0.3760.06
SODIUM (mEq/dL) 142.262.26 141.5062.01 14260.57 141.562.22
POTASSIUM (mEq/dL) 4.5861.05 4.6760.97 4.5960.09 5.4860.9
CHLORIDE (mEq/dL) 105.360.57 104.861.02 104.9562.05 104.261.02
CALCIUM (mg/dL) 10.3560.37 9.761.36 10.2860.52 10.8360.38
PHOSPHATE (mg/dL) 5.0860.25 4.9360.93 5.7360.83 6.4360.85
Serum chemistry of rats following clopidogrel treatment in PG-PS-induced arthritis model (day 21). Values are mean 6 SD, (n=6). There are no statistical differences
among groups.
doi:10.1371/journal.pone.0026035.t001
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26035Figure 5. Plasma cytokine levels in rats following clopidogrel administration in PG-PS-induced arthritis model (day 21). Plasma IFN-c,
IL-b and IL-6 levels were elevated in the PG-PS-induced arthritis-treated clopidogrel group. In contrast, plasma levels of IL-10 were significantly lower
in the PG-PS-induced arthritis rats compare to the PG-PS-induced arthritis animals alone. Plasma PF4 levels rose in PG-PS-induced arthritis animals
(alone and with treatment with clopidogrel; however, no significant differences were observed between these two groups). There were no changes
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are consistent with published studies [30,31], and a further
increase in these cytokines is correlated with the increase of
inflammation observed by clopidogrel treatment. Patients afflicted
with RA display a similar cytokine profile, including increased
circulating levels of IL-1, IFN-c and IL-6, similar to the increased
levels we observed in the rat model with PG-PS in conjunction
with clopidogrel [32]. Swennen et al., [33,34] reported an increase
of IL-10 release upon stimulation of the P2Y12 receptor. Those
findings may explain the dramatic decrease in IL-10 plasma levels
observed in the PG-PS-induced arthritis animals treated with
clopidogrel, and might thus explain why clopidogrel enhanced the
inflammatory responses induced by PG-PS. This last effect
indicates that clopidogrel might disrupt the natural cytokine
cascade response as a result of an inflammatory insult induced by
PG-PS, in which IL-10 becomes elevated in response to tumor
necrosis factor (TNF)-a and IL-1.
Thrombocytosis was observed in the PG-PS+clopidogrel group
but not in any of the other three groups during the chronic phase
of inflammation. This finding might be related to platelet
production by the bone marrow in response to inflammation.
There was a trend towards a higher platelet count in the PG-PS
group but this was not statistically different when compared to
clopidogrel alone or with the untreated group. In contrast, we
observed significant leukocytosis in the PG-PS and PG-PS+clopi-
dogrel groups; in particular, the neutrophil count in the PG-PS
group was significantly increased when compared to the
clopidogrel and untreated groups. Thus, the leukocytosis observed
in the PG-PS+clopidogrel group was due primarily to the addition
of PG-PS. The differences between PG-PS and PG-PS+clopido-
grel groups could be the result of certain metabolites of clopidogrel
that may be acting on inflammatory cells as non-specific agonists.
This last scenario may explain the increased levels of circulating
pro-inflammatory cytokines characterizing the PG-PS+clopidogrel
group. Whether the effects of clopidogrel on enhanced inflamma-
tory responses are due to off-target effects of clopidogrel or its
metabolites, or to a specific effect of the active metabolite on the
platelet P2Y12 receptor remains to be established.
Previous studies using a K/BxN serum arthritis-induced murine
model demonstrated the important role that platelet micro-
particles play during the inflammatory changes observed in this
animal model. The addition of clopidogrel increased ankle joint
thickness and inflammation [19], in agreement with our findings;
equally important, the clopidogrel side effect is observed in both
mice and Lewis rats. Notably, clopidogrel has been of therapeutic
benefit in other models used to study autoimmunity such as
systemic lupus erythematosus where clopidogrel prevented kidney
inflammation [35]. These last findings are not in discrepancy with
our findings or those from Boilard et al. [19], since the
pathophysiology of SLE is different from the one seen in RA.
Although our studies in rats cannot be directly extrapolated to
human disease (RA), countless studies using the PG-PS rat model
have beenshown to correspond to human RA [14,36], and thus this
model is widely accepted in the scientific community for the study of
the pathophysiology of RA. The fact that similar changes were
observed in mice treated with clopidogrel [19] is supportive of our
observations and it provides an additional experimental control tool
(mousemodel)toinvestigatethemechanismofaction.Furthermore,
although we used a dose of clopidogrel which is much higher than
the dosage used clinically in humans, this strategy was carefully
designed after previously standardized animal studies [37,38] to
enforce extensive arthritic responses. Thus, this model allowed us to
investigate pronounced effects of PG-PS and clopidogrel in our rat
models but these effects may be attenuated in clinical settings.
Observations from this study have translational clinical implica-
tions as the number of clinical reports in humans developing acute
arthritis as a result of clopidogrel treatment is steadily rising
[31,39,40,41,42,43,44]. These results point to potential concerns of
clopidogrel treatment in patients with chronic arthritis, particularly
rheumatoid arthritis, since those patients display a high cardiovas-
Figure 6. Platelet aggregation studies using 2MeSADP in PG-
PS-induced arthritis model. Effect of 100 nM of 2MeSADP on
platelet aggregation in isolated platelets from untreated animals,
clopidogrel-treated animals, PG-PS-induced arthritis animals and PG-PS-
induced arthritis+clopidogrel-treated animals. Traces are representative
of three independent experiments.
doi:10.1371/journal.pone.0026035.g006
between groups in IL-4 plasma levels. Values represent the mean 6 SEM, (n=4), untreated group (black bar), clopidogrel group (white bar), PG-PS
group (light gray bar) and PG-PS treated with clopidogrel group (dark gray bar), * p,0.05 PG-PS-induced arthritis group vs. PG-PS-induced arthritis
treated with clopidogrel group.
doi:10.1371/journal.pone.0026035.g005
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clopidogrel. Therefore,the datafrom ourstudy stronglysuggest that
the use of clopidogrel should be used cautiously in patients with
inflammatory diseases such as rheumatoid arthritis. In summary,
this study utilizing the PG-PS-induced acute and chronic arthritis
animal model provides compelling evidence for pro-inflammatory
activity of clopidogrel treatment at least under the experimental
conditions used. The pro-inflammatory effect of clopidogrel in the
presence of PG-PS should be further evaluated to determine the
mechanism(s) of action responsible for this detrimental effect.
Materials and Methods
Reagents
Purified, sterile PG-PS polymer from the cell walls of Group A,
type 3, strain D58 Streptococcus pyogenes was obtained from BD Lee
Laboratories (Grayson, GA). Clopidogrel was provided as 75 mg
PlavixH tablets from Bristol-Myers Squibb/Sanofi Pharmaceutical
partnership, New York, NY. A vehicle solution for clopidogrel,
carboxyl methyl cellulose (CMC) and 2 MeSADP (2-methyl-thio-
ADP) was purchased from Sigma-Aldrich Chemicals, St. Louis,
MO. ELISA kits for IL-6 and IL-10 were purchased from R&D
systems, Minneapolis, MN and IL-1b from Assay Designs Inc.
Ann Arbor, MI. All other chemicals and reagents were purchased
from Thermo Fisher Scientific Co, Waltham, MA.
Special equipment used in this study include: the Ultra-Call
Mark III digital caliper to measure the ankle joint diameter (F.V.
Flower Co. Inc., Newton, MA); the EZ 1500, anesthesia System
from Euthanex Corp. (Palmer, PA) for isofluorane (VetOne
Pharmaceuticals) to anesthetize the animals and the automatic
HemavetH Multispecies Hematology Systems (Drew Scientific,
Inc. Oxford, CT) to count blood cells.
Induction and Assessment of Arthritis
The Institutional Animal Care and Use Committee of Temple
University School of Medicine approved this experimental
protocol (approval number # ACUP3212). A total of 48 female
pathogen-free Lewis rats (8-week old) weighing between 160–180
grams were used (Charles River Laboratories, Raleigh, NC).
Animals were randomly separated into 4 different groups and
studied for 5 days, acute phase; and 21 days, chronic phase. The
untreated group received no treatment. The clopidogrel group
received a 30 mg/kg daily oral dose of clopidogrel in 0.5% CMC
(higher dose than the standard used in daily clinical practice in
humans to magnify the therapeutic effect in animals; however, this
dose has been used and standardized previously in animals)
[37,38]. The PG-PS group received a single dose of PG-PS 15 mg
of rhamnose/gram of mean body weight, administered by i.p.
injection on day 0, followed by oral administration of vehicle. The
PG-PS+clopidogrel group received a single i.p. dose of PG-PS on
day 0, followed by a daily oral dose of 30 mg/kg clopidogrel
[37,38]. Animals were weighed and examined daily. Under
anesthesia, ankle diameter was measured and arthritis severity
was assessed as previously described [29]. At times of sample
collection (day 5 and 21), rats were anesthetized, and blood
samples were collected by cardiac puncture for hematology,
plasma separation and for serum collection for chemical analyses,
using a 10:1 ratio of blood in 3.8% sodium citrate as
anticoagulant. Hematology studies were performed using the
HemavetH system. Serum samples were sent for chemistry analyses
in Charles River Laboratories (Wilmington, MA). From each
group, 4 animals were sacrificed on day 5 and 8 animals on day
21. After blood collection, animals were euthanized by cervical
dislocation and tissue samples were collected.
Plasma Preparations
Plasma was separated from blood cells by centrifugation in
polypropylene tubes at 22uC at 1006g for 10 min. The platelet
rich plasma was centrifuged at 22uC at 4006 g for 10 min.
Platelet-poor plasma was recovered and aliquots of supernatant
were stored at 270uC for cytokine profile studies. Platelet pellets
after centrifugation were resuspended in Tyrodes buffer (pH 7.4)
containing 0.05 units/ml apyrase.
Histopathology
Hind paws from all rats were collected, fixed in 4% buffered
para-formaldehyde, decalcified in 5% formic acid and embedded
in paraffin. Five micrometer sections were stained using
hematoxylin and eosin for microscopic examination. A score
system was utilized to determine the hind paw histopathological
score. This system was used in this animal model by Espinola et al.
[27] and was modified from the human scoring scale for
rheumatoid arthritis patients made by Rooney and colleagues
[45,46]. For this purpose, eight pathological parameters were
measured: synovium hyperplasia (# of cell depth), proliferative
blood vessels (# of vessels per high power field (HPF)), sub-
synovial fibrosis (percentage), inflammatory infiltrates (percentage
of infiltrated vessels per HPF), intra-articular exudates, percentage
of intra-articular space, cartilage erosion and subchondral
inflammation. Each parameter received a severity value from 0
to 3. The histopathological score for each slide was the sum of the
eight parameters (from 0 to 24) and the score means 6 standard
error from each group were plotted.
Cytokine Profile
Plasma levels of IL-1b, IL-4, IL-6, IL-10, and IFN-c were
measured by the LuminexH System using rat-specific antibodies
(Cytokine core laboratory of the University of Maryland School of
Medicine). Plasma levels of IL-1b, IL-6, IL10 and PF4 were
analyzed by ELISA, following the manufacturer’s directions (PF4:
Allied Biotech, Inc. Ijamsville, MD).
Platelet Aggregation Studies
Aggregation of 0.5 mL washed platelets was analyzed using a
P.I.C.A. Lumiaggregometer (Chrono-log Corp., Havertown, PA).
Aggregation was measured using light transmission under stirring
conditions (900 rpm) at 37uC. Each sample was allowed to
aggregate for at least 3 min. The chart recorder (Kipp and Zonen,
Bohemia, NY) was set for 0.2 mm/sec.
Statistical Analysis
Data are presented as mean 6 standard error of the mean
(SEM) for each group. The joint diameter was analyzed as a
continuous variable of all analyses. Statistical analysis of all the
data was performed using one-way ANOVA; Bonferroni’s
Multiple Comparison Test was used as post-test analyses.
P,0.05 was considered to be significant.
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